Table 1.
Participants’ baseline characteristics.
| Suboptimal Immune Response, SIR (n = 29) |
Non-SIR (n = 346) |
Total (n = 375) |
P-value | |
|---|---|---|---|---|
| Sex, n (%) | 0.029 | |||
| Female | 7 (24.1) | 156 (45.1) | 163 (43.5) | |
| Male | 22 (75.9) | 190 (54.9) | 212 (56.5) | |
| Age in years, median (IQR) | 38 [34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44] | 34 [30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40] | 34 [30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40] | 0.015 |
| BMI, median (IQR) | 19.3 (17.9–21.9) N = 11 |
20.5 (18.5–22.6) N = 180 |
20.5 (18.5–22.5) N = 191 |
0.31 |
| Pre-ART CD4 cell count, cells/mm3, median (IQR) | 50 (18–84) | 100 (34–151) | 89 (33–148) | 0.005 |
| Pre-ART HIV-RNA, log10copies/mL, median (IQR) | 4.5 (4.2–4.8) | 4.8 (4.4–5.3) | 4.8 (4.3–5.3) | 0.012 |
| CDC clinical staging, n (%) | 0.44 | |||
| A | 7 (24.1) | 122 (35.3) | 129 (34.4) | |
| B | 14 (48.3) | 152 (43.9) | 166 (44.3) | |
| C | 8 (27.6) | 72 (20.8) | 80 (21.3) | |
| CMV DNA, copies/mL, n (%) | N = 26 | N = 208 | N = 234 | 0.002 |
| <44 (lower limit of detection) | 26 (100.00) | 157 (75.5) | 183 (78.2) | |
| ≥44 | 0 (0.00) | 51 (24.5) | 51 (21.8) | |
| Hepatitis B coinfection, n (%) | 6 (21.4) N = 28 |
61 (20.5) N = 298 |
67 (20.6) N = 326 |
0.90 |
| Hepatitis C coinfection, n (%) | 3 (11.1) N = 27 |
18 (5.8) N = 308 |
21 (6.3) N = 335 |
0.23 |